Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is scheduled to announce its earnings results before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The firm had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The firm’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the same period last year, the company earned ($0.47) EPS. On average, analysts expect Ionis Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at $54.16 on Friday. The company has a current ratio of 5.03, a quick ratio of 5.00 and a debt-to-equity ratio of 2.47. The firm has a market capitalization of $6,735.07, a price-to-earnings ratio of 257.90 and a beta of 2.90. Ionis Pharmaceuticals, Inc. has a twelve month low of $26.70 and a twelve month high of $65.51.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/ionis-pharmaceuticals-inc-ions-to-release-quarterly-earnings-on-tuesday/1679772.html.

In related news, SVP Patrick R. O’neil sold 1,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $55.00, for a total value of $55,000.00. Following the completion of the transaction, the senior vice president now owns 10,633 shares in the company, valued at approximately $584,815. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 27,500 shares of the firm’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $52.89, for a total value of $1,454,475.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,636 shares of company stock valued at $5,723,915. Company insiders own 2.13% of the company’s stock.

A hedge fund recently raised its stake in Ionis Pharmaceuticals stock. The Manufacturers Life Insurance Company increased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 9.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,744 shares of the company’s stock after acquiring an additional 311 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Ionis Pharmaceuticals were worth $190,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 89.01% of the stock is currently owned by institutional investors.

A number of analysts have weighed in on the company. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 target price for the company in a report on Friday, October 27th. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Stifel Nicolaus restated a “hold” rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Goldman Sachs Group, Inc. (The) restated a “sell” rating and set a $30.00 target price on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Finally, BMO Capital Markets restated an “outperform” rating and set a $69.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $49.64.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.